Heidelberg

• A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Ch … Ended
  2024-516988-87-00 4 2022-11-09 Chronic Inducible Urticaria
• Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab Combination in HER2-Negative BRCAm Breast Cancer Ended
  2023-503529-20-00 4 2022-10-17 BRCA Mutations and Early Stage HER2-Negative Breast Cancer
• Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended
  2024-512856-40-00 5 2022-09-21 Giant Cell Arteritis
• Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and … Ended
  2024-514788-24-00 5 2022-09-20 Chronic stable plaque psoriasis
• Early Reperfusion Therapy for Recovery of Vision in Acute Central Retinal Artery Occlusion Ended
  2023-507388-21-00 5 2022-09-08 Acute non-arteritic central retinal artery occlusion (CRAO)
• A 4-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 m … Ended
  2022-500244-37-00 4 2022-08-25 COVID-19
• A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm … Ended
  2024-513658-31-00 4 2022-08-08 Idiopathic Sudden Sensorineural Hearing Loss
• Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial hypertension … Ended
  2023-509695-42-00 4 2022-07-25 Pulmonary vascular disease
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th … Ended
  2024-515485-14-00 5 2022-07-07 Acute major bleeding in patients receiving DOAC therapy with factor Xa
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 10 2022-06-30 Pulmonary Arterial Hypertension (PAH)
• Treprostinil Palmitil Inhalation Powder for Pulmonary Arterial Hypertension Ended
  2023-505541-99-00 4 2022-06-28 Pulmonary Arterial Hypertension
• A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and re … Ended
  2023-507140-37-00 4 2022-06-22 Adult patients with relapsed and refractory multiple myeloma
• A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SPIRONOLACTONE FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTH … Ended
  2024-516884-10-00 5 2022-06-22 RHEUMATOID ARTHRITIS
• A study to test BI 764198 in people with a type of kidney disease called focal segmental glomerulosclerosis Ended
  2024-511706-23-00 4 2022-05-31 Focal segmental glomerulosclerosis
• A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon … Ended
  2023-506981-30-00 4 2022-05-25 Chronic kidney disease in type 2 diabetes mellitus
• A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling Ended
  2023-508617-16-00 9 2022-05-22 Solid Tumors Dependent on KIT or PDGFRA Signaling
• RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Ended
  2023-505441-69-00 5 2022-05-17 refractory, advanced gastro-oesophageal cancer
• A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients. Ended
  2023-509139-16-00 5 2022-05-13 Therapeutic confirmatory (phase III)
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• A Phase 2 Study of Sotatercept for Combined Postcapillary and Precapillary Pulmonary Hypertension Treatment Ended
  2023-509141-12-00 4 2022-04-28 Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH
• A study to evaluate Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality Ended
  2023-509140-10-00 5 2022-04-05 Pulmonary Arterial Hypertension (PAH)
• Cabozantinib in combination with Avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3 … Ended
  2024-513518-37-00 4 2022-03-15 Advanced neuroendocrine neoplasias G3 (NEN G3) (excluding SCLC and Mer
• Effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis … Ended
  2024-510869-42-00 4 2022-02-28 aortic stenosis patients with high fibrotic burden

Showing 649–672 of 732 trials